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Background: A large body of evidence suggests that long-acting β2-adrenoceptor agonist 
(LABA)/long-acting muscarinic antagonist (LAMA) combinations induce a strong synergistic 
bronchodilatory effect in human isolated airways. Moreover, a recent post hoc analysis demon-
strated clinical synergism between LABAs and LAMAs, which induces a synergistic improve-
ment not only in lung function but also in dyspnea in COPD patients.
Aim: The aim of this study is to examine the baseline factors related to improvement in lung 
function or clinical symptoms that results from the administration of LAMA or LAMA/LABA 
and to compare the differences in improvement in lung function or clinical symptoms between 
LAMA and LAMA/LABA.
Methods: Among 829 patients with COPD who were treated with LAMA or LAMA/LABA 
in our hospital, 112 patients (aged 40–89 years) matched the criteria. Of these 112 patients, 
71 received LAMA (LAMA group) and 41 received LAMA/LABA (LAMA/LABA group) as 
the initial treatment. Various examination results such as lung function test values, symptom 
change, and frequency of exacerbations were compared between the two groups.
Results: Compared with the monotherapy, the combination therapy significantly improved 
the FEV
1
, inspiratory capacity (IC), and total COPD assessment test (CAT) scores. Comparing 
the improvement in each domain of the CAT produced by the combination therapy with that 
of the monotherapy, larger improvements were found for the domains of going out and sleeping. 
The frequency of exacerbations during the 24 weeks was significantly lower in the combination 
therapy group than in the LAMA monotherapy group (P=0.034). Although no relationship was 
found between improvement in FEV
1
 and any pretreatment factors in the LAMA/LABA group, 
the improvement in the CAT score was strongly related to the baseline CAT score, smoking 
index, and air trapping index (P-value ,1×10−4).
Conclusion: In this study of clinical practice, we found that LAMA/LABA combination therapy 
improved the clinical symptoms of COPD and IC and that the effects of the combination therapy 
were consistent with those observed in previous clinical trials.
Keywords: COPD, COPD assessment test, FEV
1
, LAMA, LAMA/LABA
Introduction
COPD is a lung disease characterized by persistent and incompletely reversible airflow 
limitation and is associated with an abnormal response of the lungs to noxious particles 
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or gases. COPD is one of the most common respiratory dis-
eases in older people, and the third cause of morbidity and 
mortality worldwide, with a high and growing prevalence.1
Dual bronchodilator therapy is the cornerstone of COPD 
treatment.2 A fixed-dose combination of an LABA and an 
LAMA improves lung function, dyspnea, quality of life, 
and exercise tolerance and reduces the risk of exacerbations 
of COPD, leading to unquestionable clinical benefits when 
compared with bronchodilator monotherapy.3,4 In the current 
strategies, treatment with single-agent bronchodilators is 
recommended for patients with milder disease and LABA/
LAMA combination therapy for patients with moderate or 
more severe COPD.5
The rationale for combining two bronchodilators with 
different mechanisms of action is to induce synergism in 
the therapeutic efficacy, reduce the overall risk of adverse 
events, and allow significant dose reductions for a given 
effect. In addition, the toxicities of the drugs should not 
overlap.6 A large body of evidence suggests that LAMA/
LABA combinations induce a strong synergistic broncho-
dilatory effect in human isolated airways.7,8 Moreover, a 
recent post hoc analysis demonstrated clinical synergism 
between LABAs and LAMAs, which induces a synergistic 
improvement not only in lung function but also in dyspnea 
in COPD patients.9
In the current study, we examined whether LAMA/
LABA combination therapy in the actual clinical setting in 
Japan shows comparable efficacy with that found in clinical 
trials in non-Japanese populations. We compared improve-
ments in lung function and clinical symptoms obtained 
with a single agent of LAMA with those obtained with a 
combination therapy of LAMA and LABA in patients with 
stage I–IV COPD.
Methods
Participants
We studied 829 patients with newly diagnosed COPD who ini-
tiated LAMA or LAMA/LABA treatment from 2011 to 2018 
at our hospital (Hitachinaka General Hospital, Hitachinaka, 
Japan). They had never used bronchodilators before. Of 
those, 717 patients were excluded on the basis of the follow-
ing criteria: 1) the treatment was interrupted owing to side 
effects (arrhythmia: LAMA 1, LAMA/LABA 1; increased 
urinary frequency: LAMA 1); 2) the initial treatment was 
not administered at our hospital (n=232); 3) ICS therapy was 
given during the observation period, and comorbid asthma 
was diagnosed by a respiratory specialist (n=316); 4) a regular 
examination was unavailable for at least 24 weeks (n=78); 
and 5) respiratory function testing was not available before 
and after treatment (n=91) (Figure 1). Of the remaining 112 
patients, aged 40–89 years, 71 received LAMA (tiotropium, 
n=65; glycopyrronium, n=2; and acridinium, n=4), and 41 
received LAMA/LABA (tiotropium/indacaterol, n=5; tiotro-
pium/olodaterol, n=29; and glycopyrronium/indacaterol, 
Figure 1 Flowchart of recruitment of COPD patients.
Abbreviations: laBa, long-acting β2-adrenoceptor agonist; laMa, long-acting muscarinic antagonist; ICs, inhaled corticosteroid.
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n=7) as the initial treatment. The study protocol was approved 
by the institutional review board of Hitachinaka General 
Hospital (No. 17-008). We obtained written informed con-
sent from the patients, with the exception of patients who 
had already died or who had stopped visiting us for reasons 
such as transfers. All patient data were maintained with strict 
confidentiality; therefore, the institutional review board of 
Hitachinaka General Hospital waived informed consent from 
the deceased or transferred patients.
lung function tests
Spirometry using an electronic spirometer was performed 
with the patient in standing position, and in accordance with 
the criteria established by the Japanese Respiratory Society 
(JRS).10 None of the patients used bronchodilators before 
spirometry. The patients performed up to three forced expi-
ratory maneuvers to obtain acceptable results. Well-trained 
respiratory technicians continuously monitored the spirom-
etry procedure and reviewed the flow–volume curves to 
ensure adherence to the standards. Data for %FEV
1
, %FVC, 
IC, and FEV
1
/FVC were obtained from all the patients.
We compared the lung function before and after the 
LAMA or LAMA/LABA treatments. The “before treatment” 
lung function was measured 2 weeks before the treatment, and 
the “after treatment” lung function was measured 4–12 weeks 
after the treatment. Lung function values were measured 
2–8 hours after the inhaled dose. The time points for the 
“before” and “after” treatment lung function measurements 
were identical for each patient. The inhalation technique for 
both treatments was confirmed to be appropriate.
COPD exacerbations
A COPD exacerbation was defined as one of the following: 
1) addition of antibiotics with or without an antitussive 
expectorant within 24 weeks of the initial administration; 
2) an unexpected consultation within 24 weeks of the initial 
administration; and 3) hospitalization due to a respiratory 
disease within 24 weeks of the initial administration.
COPD assessment test
COPD status was assessed using the CAT. The CAT is a 
disease-specific questionnaire to assess the health status of 
individuals with COPD. It consists of eight questions related 
to cough, expectoration, dyspnea, chest tightness, going up 
hills/stairs, confidence in leaving home, activity limitations 
at home, and levels of energy and one question assessing the 
impact of COPD on sleep. Each question is assessed on a 
five-point scale, providing a total score ranging from 0 (floor) 
to 40 (ceiling), with higher scores indicating a more severe 
impact of COPD on a patient’s life.11,12
statistical analyses
The changes in lung function (VC, FVC, FEV
1
, IC) and CAT 
scores after 24 weeks of LAMA or LAMA/LABA treatment 
were assessed using Student’s t-test, and the frequencies of 
exacerbations during the 24 weeks of treatment were compared 
between LAMA and LAMA/LABA groups using Pearson’s 
chi-squared test. We used univariate and multivariate analyses 
to examine pretreatment factors related to improvements in 
FEV
1
 or CAT score obtained with LAMA or LAMA/LABA. 
The variables incorporated in these models were age at the 
beginning of treatment, pack years of smoking history, CAT 
scores, and lung function test values before treatment. The 
changes in every CAT domain obtained with the single LAMA 
treatment were compared with those obtained with the com-
bined LAMA/LABA treatment using Student’s t-test. Lastly, 
we also examined the relationship between improvement in 
CAT scores and improvement in lung function measures.
Results
Patients’ characteristics
The patients’ demographics and characteristics are summa-
rized in Table 1. No statistical difference was found in any 
factor between the two groups.
Table 1 Patients’ demographics and baseline characteristics
Characteristics LAMA 
group (n=71)
LAMA/LABA 
group (n=41)
P-value
age (years) 71.5±7.6 68.9±10.9 ns
Female sex, n (%) 6 (8.5) 3 (7.3) ns
Pack years 45.6±26.5 39.9±42.4 ns
CaT 12.4±6.8 (n=38) 9.7±6.2 (n=25) ns
VC (l) 3.2±0.88 3.2±0.80 ns
Predicted VC (%) 100.5±22.4 95.1±19.7 ns
FVC (l) 2.97±0.88 2.90±0.77 ns
Predicted FVC (%) 93.7±22.9 87.4±18.3 ns
FeV1 (l) 1.62±0.58 1.69±0.57 ns
Predicted FeV1 (%) 69.7±21.4 67.1±17.0 ns
FeV1/FVC (%) 54.1±10.6 58.0±9.91 ns
IC (l) 1.93±0.63 1.83±0.57 ns
V25 0.25±0.13 0.30±0.18 ns
V50/V25 3.49±1.46 3.72±1.40 ns
air trapping index 7.63±10.2 8.25±8.6 ns
stage (n) I 22/II 35/
III 13/IV 1
I 10/II 23/
III 8/IV 0
ns
Notes: Data are presented as mean ± sD unless otherwise indicated. There was no 
statistical difference in each factor between the two groups. V25, expiratory airflow 
rate at 25% vital capacity. V50/V25, ratio of the airflow rate at 50% vital capacity to 
the airflow rate at 25% vital capacity. Air trapping index: ratio of [VC − FVC] to VC.
Abbreviations: CaT, COPD assessment test; IC, inspiratory capacity; laBa, 
long-acting β2-adrenoceptor agonist; laMa, long-acting muscarinic antagonist; 
NS, nonsignificant; VC, vital capacity.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
15
8.
56
.1
02
 o
n 
06
-D
ec
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2018:13submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3144
Yamada et al
Comparison of therapeutic effects of 
laMa and laMa/laBa
A summary of the results is shown in Table 2. The FEV
1
 and 
IC were significantly improved by the combination therapy: 
IC was improved by 241 mL. Similarly, the CAT scores were 
significantly improved by the combination therapy (mean 
change =3). When we compared the therapeutic effects of 
the single therapy with those of the combination therapy for 
each of the eight domains of the CAT, although no significant 
differences were found for cough and sputum, the domains 
of going out and sleeping were significantly improved by the 
combination therapy (Figure 2). In the LAMA group, nine of 
the 71 patients had exacerbations, and in the LAMA/LABA 
group, one of the 41 patients had exacerbations during the 
24 weeks. The frequency of exacerbations was significantly 
lower in the combination therapy group (P=0.034, one-sided 
Pearson’s chi-squared test; Table 3).
relationship between pretreatment 
factors and therapeutic effects
The relationship between all the pretreatment factors (age, 
pack years, CAT, VC, FVC, %VC, %FVC, FEV
1
, %FEV
1
, 
FEV
1
/FVC, IC, air trapping index) and therapeutic effects 
was analyzed by univariate analysis (Table 4). In the LAMA 
group, improvements in IC and baseline FEV
1
 were related, 
but IC was not related to any other factors including the 
baseline CAT score. Multivariate stepwise analysis revealed 
no significant relationships between the pretreatment factors 
and the therapeutic effects in the LAMA group.
In the LAMA/LABA group, although no relationship 
was found between improvement in FEV
1
 and any pre-
treatment factors, the improvement in the CAT score was 
strongly related to the baseline CAT score, smoking index, 
and air trapping index (Tables 4 and 5). In addition, we 
found that improvement in FVC was significantly related to 
Table 2 Therapeutic effects in the laMa group and the laMa/laBa group
Treatment n Mean SD SE P-value*
Improvement in FeV1 (l) laMa
laMa/laBa
71
41
0.084
0.212
0.185
0.194
0.022
0.030
0.005
Improvement in CaT laMa
laMa/laBa
38
25
1.000
3.960
6.307
6.059
1.023
1.212
0.034
Improvement in VC (l) laMa
laMa/laBa
71
41
0.112
0.224
0.411
0.401
0.049
0.063
0.081
Improvement in FVC (l) laMa
laMa/laBa
71
41
0.127
0.218
0.391
0.485
0.046
0.076
0.142
Improvement in IC (l) laMa
laMa/laBa
71
41
0.078
0.319
0.303
0.381
0.036
0.060
1.8×10−4
Note: *P-value for comparison of the laMa group and laMa/laBa groups (student’s t-test, one-sided).
Abbreviations: CaT, COPD assessment test; IC, inspiratory capacity; laBa, long-acting β2-adrenoceptor agonist; laMa, long-acting muscarinic antagonist; se, standard 
error; VC, vital capacity.
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Figure 2 Comparisons of improvement in each domain of CaT between the laMa/laBa and laMa groups.
Note: *P-value ,0.05, comparison of laMa and laMa/laBa groups (student’s t-test, one-sided).
Abbreviations: CaT, COPD assessment test; laBa, long-acting β2-adrenoceptor agonist; laMa, long-acting muscarinic antagonist.
 
In
te
rn
at
io
na
l J
ou
rn
al
 o
f C
hr
on
ic 
O
bs
tru
ct
ive
 P
ul
m
on
ar
y 
Di
se
as
e 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
15
8.
56
.1
02
 o
n 
06
-D
ec
-2
01
8
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
International Journal of COPD 2018:13 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
3145
Difference in effect of laMa and laMa/laBa combination in Japan
improvement in the total CAT score (Figure 3A; Table 6). 
The improvement in IC was significantly related to the 
improvement in CAT scores for the going out and sleeping 
domains (Figure 3B; Table 6).
Discussion
In this study of clinical practice in Japan, LAMA/LABA 
combination therapy showed greater effect on lung function, 
clinical symptoms, and exacerbations in patients with COPD 
(stages I–IV). With the LAMA/LABA combination therapy, 
improvement in the CAT score was obvious in patients 
with elevated baseline air trapping index and CAT scores. 
Furthermore, our findings indicated that improvement in IC 
may have led to the improvement in the CAT scores for the 
going out and sleeping domains.
The Nippon COPD Epidemiology (NICE) study 
(N=2,343) demonstrated that the prevalence of COPD in Japan 
is comparable to that in other developed countries.13 Several 
studies have compared the effects of a single LAMA agent 
Table 3 number of exacerbations in the laMa and laMa/
laBa groups
Group Exacerbation Total
Yes No
laMa 9 62 71
laMa/laBa 1 40 41
Total 10 102 112
Notes: The frequency of exacerbations was significantly lower in the combination 
therapy group (P=0.034, one-sided Pearson’s chi-squared test). The definition of 
exacerbations is provided in the COPD exacerbations section.
Abbreviations: laBa, long-acting β2-adrenoceptor agonist; laMa, long-acting 
muscarinic antagonist.
Table 4 relationships between pretreatment factors and thera-
peutic effects (univariate analysis)
Pearson correlation 
coefficient
LAMA LAMA/LABA
Baseline trait FEV1 CAT FEV1 CAT
age −0.029 −0.045 −0.254 0.029
Pack years 0.020 −0.098 −0.048 0.745**
CaT 0.112 0.316 0.084 0.857**
VC 0.050 0.066 0.121 0.145
FVC −0.018 0.158 0.148 −0.087
%VC 0.022 0.180 0.119 0.178
%FVC −0.058 0.256 0.134 −0.130
FeV1 −0.027 0.226 0.005 −0.244
%FeV1 −0.084 0.308 −0.139 −0.298
FeV1/FVC −0.007 0.200 −0.195 −0.311
IC 0.290* 0.026 0.102 −0.066
air trapping index 0.137 −0.275 −0.079 0.711**
Notes: In the laMa group, baseline IC was shown to be related to improvement 
in FeV1. Improvement in CaT was strongly related to CaT, smoking index, and air 
trapping index before treatment. *P,0.05; **P,1×10−4.
Abbreviations: CaT, COPD assessment test; IC, inspiratory capacity; laBa, 
long-acting β2-adrenoceptor agonist; laMa, long-acting muscarinic antagonist; 
VC, vital capacity.
Table 5 relationships between pretreatment factors and thera-
peutic effects (multivariate analysis)
Group Trait PF SE β t-value P-value
laMa/
laBa
Improvement 
in CaT score
CaT
aTI
0.120
0.089
0.519
0.301
4.216
2.892
3.88×10−4
0.009
PY 0.013 0.254 2.181 0.041
Abbreviations: aTI, air trapping index; CaT, COPD assessment test; laBa, 
long-acting β2-adrenoceptor agonist; laMa, long-acting muscarinic antagonist; PF, 
pretreatment factor; PY, pack year; se, standard error.
with those of an LAMA/LABA combination on FEV
1
,14,15 
clinical symptoms assessed using the Transition Dyspnea 
Index and the St George’s Respiratory Questionnaire,16 
and exacerbations17 in COPD patients. All of those studies 
reported that the combination therapy was superior to the 
single-agent therapy and that the combination therapy had no 
medication side effects. Our current findings are consistent 
with those observed in previous clinical trials.
According to the recently modified GOLD guidelines,5 the 
presence of airflow limitation is used as a diagnostic criterion, 
but symptom intensities and exacerbations are considered to be 
more important in the selection of treatment strategies. If the 
clinical score such as the CAT score is high or exacerbation is 
frequent, use of stronger bronchodilators is recommended. In 
this study, the baseline FEV
1
 did not predict improvement in 
clinical symptoms, and even among the COPD patients with 
milder airflow limitation, those with higher CAT scores at base-
line seemed to have benefited from the combination therapy.
Limitations
This study was limited by its retrospective nature and the 
fact that the patients were not randomly assigned to the treat-
ments. Furthermore, we could not perform uniform guidance 
of the inhalation technique, and there were periods during 
which only LAMA could be prescribed.
Conclusion
The present study found that LAMA/LABA combination 
improved the clinical symptoms of COPD and IC and that 
the effects of the combination therapy were consistent with 
those observed in previous clinical trials. In the future, 
randomized clinical trials may reveal the significance of 
LAMA/LABA combination therapy even in COPD patients 
with milder severity.
Abbreviations
CAT, COPD assessment test; IC, inspiratory capacity; ICS, 
inhaled corticosteroid; LABA, long-acting β2-adrenoceptor 
agonist; LAMA, long-acting muscarinic antagonist; VC, 
vital capacity.
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Figure 3 (A) relationship between improvement in FVC and improvement in total CaT score in 63 COPD patients with CaT data. (B) relationship between improvement 
in IC and improvement in CaT scores for going out + sleeping in 63 COPD patients.
Abbreviations: CaT, COPD assessment test; IC, inspiratory capacity.
Table 6 relationship between improvements in CaT scores and lung functions
Improvement in CAT Improvement in 
lung function
SE β t-value P-value
all domains FVC 1.780 0.257 2.074 0.042
going outside + sleeping IC 0.624 0.255 2.060 0.044
Abbreviations: CaT, COPD assessment test; IC, inspiratory capacity; se, standard error.
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